Marketing-authorisation holder
Exelixis Inc
2 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CABOMETYX20mg base | 40mg base | 60mg base · Tablet | Cabozantinib s-malate | United States | Marketed | 2016 |
| COMETRIQ20mg base | 80mg base · Capsule | Cabozantinib s-malate | United States | Marketed | 2012 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 2 | 2 | 0 | CompaniesAll medicines |
Top substances
The active substances in most of its medicines.
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 2
- Countries
- 1
- Roles
- Authorisation holder
Work with Prognia
Keep Exelixis Inc’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a call